JP4616237B2 - シリコン化合物薄膜の形成方法 - Google Patents
シリコン化合物薄膜の形成方法 Download PDFInfo
- Publication number
- JP4616237B2 JP4616237B2 JP2006301357A JP2006301357A JP4616237B2 JP 4616237 B2 JP4616237 B2 JP 4616237B2 JP 2006301357 A JP2006301357 A JP 2006301357A JP 2006301357 A JP2006301357 A JP 2006301357A JP 4616237 B2 JP4616237 B2 JP 4616237B2
- Authority
- JP
- Japan
- Prior art keywords
- film
- plasma
- rare earth
- substrate
- chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Physical Vapour Deposition (AREA)
- Chemical Vapour Deposition (AREA)
- Formation Of Insulating Films (AREA)
Description
Claims (4)
- 成膜室の内部に膜形成対象の基板を載置する第1工程と、
前記成膜室とこれにプラズマ引出口を介して連通するプラズマ生成室との内部を真空排気する第2工程と、
前記プラズマ生成室において生成した第1プラズマを前記プラズマ引出口より引き出し、シリコンソースガスを供給している基板の表面に引き出した前記プラズマを照射して前記基板の上にシリコン化合物を堆積すると共に、
前記プラズマ生成室とは異なる位置で前記成膜室に連通するスパッタ室の内部に固定された希土類金属を含むターゲットに電力を印加して第2プラズマを生成し、この第2プラズマ中のイオンを前記ターゲットに衝突させてスパッタ現象を起こすことで、前記ターゲットを構成する希土類元素を飛び出させて前記基板に到達させ、
前記基板の上に前記希土類元素が添加された前記シリコン化合物よりなるシリコン化合物薄膜が形成された状態とする第3工程と
を備えることを特徴とするシリコン化合物薄膜の形成方法。 - 請求項1記載のシリコン化合物薄膜の形成方法において、
前記第1プラズマは、電子サイクロトロン共鳴法により生成し、発散磁界により前記プラズマ引出口より引き出して基板の表面に照射する
ことを特徴とするシリコン化合物薄膜の形成方法。 - 請求項1又は2記載のシリコン化合物薄膜の形成方法において、
前記ターゲットに印加する前記電力を制御することで、前記シリコン化合物薄膜の膜厚方向の前記希土類元素の濃度を制御する
ことを特徴とするシリコン化合物薄膜の形成方法。 - 請求項1又は2記載のシリコン化合物薄膜の形成方法において、
前記スパッタ室と前記成膜室とを連通する連通孔の前記成膜室側に配置されたシャッターの開閉により、前記ターゲットより飛び出した前記希土類元素の前記基板への到達数を制御し、前記シリコン化合物薄膜の膜厚方向の前記希土類元素の濃度を制御する
ことを特徴とするシリコン化合物薄膜の形成方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006301357A JP4616237B2 (ja) | 2006-11-07 | 2006-11-07 | シリコン化合物薄膜の形成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006301357A JP4616237B2 (ja) | 2006-11-07 | 2006-11-07 | シリコン化合物薄膜の形成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008118008A JP2008118008A (ja) | 2008-05-22 |
JP4616237B2 true JP4616237B2 (ja) | 2011-01-19 |
Family
ID=39503700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006301357A Expired - Fee Related JP4616237B2 (ja) | 2006-11-07 | 2006-11-07 | シリコン化合物薄膜の形成方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4616237B2 (ja) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05014152A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
RS52036B (en) | 2004-12-21 | 2012-04-30 | Medimmune Limited | ANGIOPOETIN-2 ANTIBODIES AND ITS USES |
AU2006332340B2 (en) | 2005-12-30 | 2013-09-26 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Extended release of neuregulin for improved cardiac function |
UA118536C2 (uk) | 2008-07-23 | 2019-02-11 | Амбркс, Інк. | Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування |
JP5924937B2 (ja) | 2008-07-25 | 2016-05-25 | エックス−ボディ インコーポレイテッド | タンパク質スクリーニング法 |
JP5709754B2 (ja) | 2008-09-26 | 2015-04-30 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 非天然アミノ酸による複製に依存する微生物およびワクチン |
AU2011210825B2 (en) | 2010-01-27 | 2017-02-02 | Children's Medical Center Corporation | Pro-angiogenic fragments of prominin-1 and uses thereof |
EP2720539B1 (en) | 2011-06-14 | 2018-10-24 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
EP2802603A4 (en) | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
EP2802601B1 (en) | 2012-01-09 | 2019-11-13 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
EP2926142B2 (en) | 2012-11-30 | 2022-07-06 | F. Hoffmann-La Roche AG | Identification of patients in need of pd-l1 inhibitor cotherapy |
EP3043824B1 (en) | 2013-09-13 | 2022-07-06 | The Scripps Research Institute | Modified therapeutic agents and compositions thereof |
EP3339318A1 (en) | 2013-09-16 | 2018-06-27 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Mutant calreticulin for the diagnosis of myeloid malignancies |
ES2741308T3 (es) | 2013-10-15 | 2020-02-10 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos |
KR102339240B1 (ko) | 2013-10-15 | 2021-12-15 | 더 스크립스 리서치 인스티튜트 | 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
EP4212180A1 (en) | 2013-12-18 | 2023-07-19 | The Scripps Research Institute | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
CA2958879A1 (en) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
US20190000928A1 (en) | 2015-06-17 | 2019-01-03 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
WO2017007955A1 (en) | 2015-07-07 | 2017-01-12 | The Research Foundation For The State University Of New York | Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species |
JP7018702B2 (ja) * | 2016-08-02 | 2022-02-14 | 神港精機株式会社 | 成膜装置及び成膜方法 |
WO2018075807A1 (en) | 2016-10-19 | 2018-04-26 | California Institute For Biomedical Research | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
EP3538100A2 (en) | 2016-11-14 | 2019-09-18 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Combination of a brd4 inhibitor and an antifolate for the therapy of cancer |
JP7166252B2 (ja) | 2016-11-30 | 2022-11-07 | メディツィーニシェ・ウニヴェルジテート・インスブルック | サイクリン依存性キナーゼ阻害剤としての3-アミノ-1,5-ジヒドロピラゾロ[3,4-d]ピリミジン-4-オン |
CA3063288A1 (en) | 2017-05-12 | 2018-11-15 | Mavalon Therapeutics Limited | Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors |
JP2020528054A (ja) | 2017-07-19 | 2020-09-17 | オークランド ユニサービシズ リミテッド | サイトカインモジュレーション |
US20210179591A1 (en) | 2017-12-05 | 2021-06-17 | Eth Zurich | New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors |
JP7611812B2 (ja) | 2018-04-06 | 2025-01-10 | ツィレンティン アーゲー | 多汗症を治療するためのブメタニド誘導体 |
WO2019193161A1 (en) | 2018-04-06 | 2019-10-10 | Universität Wien | Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs |
WO2019207051A1 (en) | 2018-04-25 | 2019-10-31 | Università Degli Studi Di Torino | Medical use of combinations of non-natural semaphorins 3 and antimetabolites |
CA3110647A1 (en) | 2018-08-28 | 2020-03-05 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
SG11202102427XA (en) | 2018-09-11 | 2021-04-29 | Ambrx Inc | Interleukin-2 polypeptide conjugates and their uses |
WO2020053808A1 (en) | 2018-09-12 | 2020-03-19 | Georg Dewald | Method of diagnosing vasoregulatory disorders |
US20220009986A1 (en) | 2018-10-19 | 2022-01-13 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
US20230067929A1 (en) | 2018-12-17 | 2023-03-02 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
JP7695885B2 (ja) | 2019-02-12 | 2025-06-19 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
WO2021021676A1 (en) | 2019-07-26 | 2021-02-04 | Amgen Inc. | Anti-il13 antigen binding proteins |
US12098212B2 (en) | 2019-08-12 | 2024-09-24 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
WO2021064141A1 (en) | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
KR102800341B1 (ko) | 2019-10-02 | 2025-04-23 | 톨레모 테라퓨틱스 아게 | 헤테로사이클릭 유도체, 약학 조성물 및 암의 치료 또는 개선에서 그들의 용도 |
WO2021074418A1 (en) | 2019-10-16 | 2021-04-22 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof |
EP4045142A1 (en) | 2019-10-16 | 2022-08-24 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof |
AU2020371784A1 (en) | 2019-10-24 | 2022-06-02 | Minotaur Therapeutics, Inc. | Chimeric cytokine modified antibodies and methods of use thereof |
JP7652791B2 (ja) | 2019-11-19 | 2025-03-27 | モダグ ゲーエムベーハー | α-シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物 |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
KR20230027294A (ko) | 2020-06-25 | 2023-02-27 | 톨레모 테라퓨틱스 아게 | 섬유성 질환의 치료, 개선 또는 예방을 위한 헤테로사이클릭 유도체, 약학 조성물 및 그들의 용도 |
EP3939578A1 (en) | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
US20230302150A1 (en) | 2020-08-20 | 2023-09-28 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
EP3964497A1 (en) | 2020-09-04 | 2022-03-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain |
EP4229081A1 (en) | 2020-10-15 | 2023-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
EP4229037A2 (en) | 2020-10-16 | 2023-08-23 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
AU2022224636A1 (en) | 2021-02-19 | 2023-09-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that neutralize sars-cov-2 |
AU2022249223A1 (en) | 2021-04-03 | 2023-10-12 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
US20240327394A1 (en) | 2021-04-07 | 2024-10-03 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
CN118251420A (zh) | 2021-04-28 | 2024-06-25 | 米诺陶治疗公司 | 人源化嵌合牛抗体和使用方法 |
EP4511013A1 (en) | 2022-04-19 | 2025-02-26 | Philera New Zealand Ltd. | Treatment of brain copper disorders |
WO2023203172A1 (en) | 2022-04-20 | 2023-10-26 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
JP2025515486A (ja) | 2022-04-29 | 2025-05-15 | ピュリノミア バイオテック, インコーポレイテッド | 好酸球駆動性疾患及び障害を治療するための方法及び組成物 |
WO2025040546A1 (en) | 2023-08-18 | 2025-02-27 | Proxygen Gmbh | Pyrazole compounds as cullin ring ubiquitin ligase compounds |
WO2025104236A1 (en) | 2023-11-15 | 2025-05-22 | Proxygen Gmbh | Pyrazole compounds as cullin ring ubiquitin ligase compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0473720A (ja) * | 1990-07-16 | 1992-03-09 | Matsushita Electric Ind Co Ltd | 非線形光学材料の製造方法 |
JP3334159B2 (ja) * | 1992-04-17 | 2002-10-15 | ソニー株式会社 | 電子サイクロトロン共鳴を用いた成膜方法及び成膜装置 |
-
2006
- 2006-11-07 JP JP2006301357A patent/JP4616237B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2008118008A (ja) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4616237B2 (ja) | シリコン化合物薄膜の形成方法 | |
US7413998B2 (en) | Biased pulse DC reactive sputtering of oxide films | |
US7469558B2 (en) | As-deposited planar optical waveguides with low scattering loss and methods for their manufacture | |
JP4273932B2 (ja) | 表面波励起プラズマcvd装置 | |
US6650816B2 (en) | Planar waveguide amplifier | |
JP2002334871A (ja) | プラズマプロセスのプラズマ電荷ダメージを低減する方法 | |
KR20080102273A (ko) | 플라즈마 산화 처리 방법 | |
JP2009054818A (ja) | プラズマ処理装置、プラズマ処理方法および終点検出方法 | |
US20040136681A1 (en) | Erbium-doped oxide glass | |
CN102714158A (zh) | 硅氧化膜的形成方法和等离子体氧化处理装置 | |
US12012649B2 (en) | Erbium-doped bismuth oxide film | |
KR101123442B1 (ko) | 반도체 장치의 제조 방법, 반도체 장치, 플라즈마 질화처리 방법, 제어 프로그램 및 컴퓨터 기억 매체 | |
JP2006047462A (ja) | 光素子及びその製造方法 | |
JP4268085B2 (ja) | 酸窒化シリコン膜の形成方法及び形成装置 | |
WO2006006681A1 (ja) | ガラス光導波路 | |
Bonneville et al. | Material optimization via optical and spectroscopic parameters of Al2O3: Er3+ for the development of amplifiers and lasers | |
JP4757841B2 (ja) | 薄膜形成装置 | |
JP4387824B2 (ja) | 酸窒化シリコン膜の製造方法 | |
WO2004023612A1 (ja) | 導波路型光増幅器及びその製造方法 | |
Bradley | Al2O3: Er3+ as a gain platform for integrated optics | |
JPH06318579A (ja) | ドライクリーニング方法 | |
KR20210124173A (ko) | 플라스마 처리 장치 및 플라스마 처리 방법 | |
JP2014173122A (ja) | ErドープZnO膜形成方法 | |
JPH0896990A (ja) | プラズマ処理装置およびプラズマ処理方法 | |
JP4650698B2 (ja) | Ecrスパッタ装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090109 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20101007 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101019 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101021 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4616237 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131029 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |